I-O newcomer's funding now nearly $170 million

TCR2 Therapeutics Inc, an immuno-oncology (I-O) company claiming to be developing a new class of T cell receptor (TCR)-based cellular therapies for both solid tumors and blood cancers, has completed an oversubscribed Series B financing of $125 million.

The funds will advance the US biotech’s TRuC-T cell programs through human proof-of-concept, including its lead solid tumor program TC-210 targeting mesothelin.

"The diversity of our investor base is a reflection of the increasing globalization of cell therapy, and this financing gives us partners who can help with our strategy in both the USA and China